WO2007009529A2 - Calcium-peptide component - Google Patents
Calcium-peptide component Download PDFInfo
- Publication number
- WO2007009529A2 WO2007009529A2 PCT/EP2006/005173 EP2006005173W WO2007009529A2 WO 2007009529 A2 WO2007009529 A2 WO 2007009529A2 EP 2006005173 W EP2006005173 W EP 2006005173W WO 2007009529 A2 WO2007009529 A2 WO 2007009529A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- calcium
- peptide component
- preparation
- agent
- glycomacropeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the invention relates to a calcium-peptide component and their use Phyg.
- Calcium may have a palliative effect on depression, anxiety, and mood disorders associated with the premenstrual syndrome (S. Thys-Jacobs, J Amer Coli Nutr 19, 220-227 (2000); ER Bertone Johnson et al., Arch Intern Med , 1246-52 (2005))
- S. Thys-Jacobs J Amer Coli Nutr 19, 220-227 (2000); ER Bertone Johnson et al., Arch Intern Med , 1246-52 (2005)
- milk is the most important source of calcium.
- the consumption of milk has declined significantly in recent years as so-called cow's milk intolerance has increasingly increased in the Central European population.
- other dairy products can be used instead of milk, but consumers' consumption habits are often still in conflict. Because of this, calcium is added to foods that do not normally contain it.
- the object of the invention is therefore to develop a source of calcium for products that provide calcium in a soluble form.
- a calcium-peptide component of the aforementioned type which contains at least one calcium salt, cagedophosphopeptides and glycomacropeptide.
- Amount of calcium in proteins It is known from milk that the calcium is evenly distributed in the liquid and not at the bottom in the form of sediment is deposited.
- the calcium in the milk is mainly bound to the so-called caseins, a part of the milk proteins.
- the caseins have the disadvantage of precipitating in the acid so that the bound casein calcium is unsuitable for acidic products.
- caseinophosphopeptides which bind calcium particularly well.
- Such caseinophosphopeptides are commercially available today (eg CPP DMV). Through the use of caseinophosphopeptides, it is now possible to achieve largely clear calcium solutions.
- glycomacropeptide In the production of cheese, the action of the rennet casein releases the glycomacropeptide. This glycomacropeptide is located after cheese production in the so-called whey fraction.
- the glycomacropeptide is a fragment of ⁇ -casein with the amino acid
- Glycomacropeptide also contains a phosphate group which can bind calcium to itself.
- the weight ratio between the calcium salts, caseinophosphopeptide and glycomacropeptide is preferably 1 - 5: 0.5 - 2.5: 1.5 - 7.5. Furthermore, the addition of minerals and / or trace elements is conceivable. In order to avoid problems of deposition of calcium in the blood vessels, magnesium may additionally be added to the calcium-peptide component according to the invention. All magnesium salts permitted under the food law can be added. The daily amount recommended is a maximum of 250 mg of magnesium.
- vitamins are also added; especially vitamin D, which is responsible for the absorption of calcium in the small intestine.
- soluble fiber such as oligofructose or galactooligosaccharides, and / or phytosterols is a preferred embodiment of the component according to the invention.
- Suitable calcium salts are all food-approved salts. Here are some to name: calcium carbonate, calcium chloride, calcium citrate, calcium gluconate, calcium glycerophosphate, calcium, calcium orthophosphate, calcium oxide and / or calcium hydroxide.
- the calcium-peptide component according to the invention has a weight-reducing property in animal experiments.
- rats for example, a lower weight gain and significantly lower fat gain could be recorded.
- the same effect could also be demonstrated in patients complaining of weight problems.
- Another invention therefore also relates to the use of the calcium-peptide component according to the invention as a medicament, for the preparation of an agent for regulating body weight or for improving calcium absorption. Moreover, the invention relates to the use of the calcium-peptide component for the preparation of an agent for regulating blood pressure and for producing an agent for alleviating the symptoms of premenstrual syndrome.
- the invention also relates to the use of the three main components calcium salts, caseinophosphopeptides and glycomacropeptides for the preparation of preparations for weight reduction.
- the calcium-peptide component according to the invention can be offered both as additives in foods, as a dietary supplement or as a pharmaceutical preparation.
- the calcium-peptide component according to the invention is versatile, in particular imaginable as candy, powder, tablets, compacted forms, bars, jellies or emulsions.
- Typical application examples are the use in fruit juices, quark and yoghurt foods, whey drinks, desserts, ice cream, calcium tablets or fruit jars.
- the calcium-peptide component according to the invention can be composed as follows (the recommended daily dose is given as an example):
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Calcium-Peptid-Komponente Calcium-peptide component
Die Erfindung betrifft eine Calcium-Peptid-Komponente und deren Verwen- düng.The invention relates to a calcium-peptide component and their use düng.
Die Versorgung des menschlichen Körpers mit Calcium ist eines der wichtigsten Ziele der heutigen Zeit, da Calciummangelzustände für einige typische Zivilisationskrankheiten verantwortlich sind.Supplying the human body with calcium is one of the most important goals of our times, as calcium deficiencies are responsible for some typical lifestyle diseases.
Eine ausreichende Versorgung mit Calcium ist heute während des gesamten Lebens notwendig. Wird Calcium nicht bereits in der frühen Jugend in ausreichenden Mengen dem Körper zugeführt, so treten relativ früh eine Unterversorgung der Knochen und im späteren Alter die so genannten Osteoporose auf. Die mangelnde Calciumzufuhr bewirkt eine Reduzierung der Knochendichte. Bevor es jedoch zur Krankheit Osteoporose kommt, führt Calcium- mangel zu zahlreichen Störungen des Stoffwechsels. Symptome sind erhöhte Erregbarkeit der Nerven und Muskeln, die zu Muskelkrämpfen führen können.An adequate supply of calcium is necessary throughout life today. If calcium is not supplied to the body in sufficient quantities in early adolescence, there is a shortage of bone supply relatively early on, and so-called osteoporosis later in life. The lack of calcium intake causes a reduction in bone density. However, before the disease osteoporosis occurs, calcium deficiency leads to numerous disorders of the metabolism. Symptoms include increased excitability of the nerves and muscles, which can lead to muscle cramps.
Calcium ist in den letzten Jahren auch zunehmend im Zusammenhang mit Gewichtskontrolle bei fettleibigen Menschen in der wissenschaftlichen Literatur diskutiert worden. Hierbei sind verschiedene Mechanismen zur Erklärung herangezogen worden. Einerseits wird die Wirkung des Calciums über eine hormonähnliche Wirkung beschrieben (Zemel, MB, J Am Coli Nutr 21,Calcium has also been increasingly discussed in recent years in the context of weight control in obese people in the scientific literature. Various mechanisms have been used to explain this. On the one hand, the effect of calcium on a hormone-like action is described (Zemel, MB, J Am Coli Nutr 21,
S. 146 bis 151, 2002). Dieses Wirkprinzip ist u. a. in den Patenten US 6,384,087 oder EP 1 343 390 beschrieben.Pp. 146-151, 2002). This principle is u. a. in patents US 6,384,087 or EP 1 343 390.
Es wird davon ausgegangen, dass Calcium durch Bildung von Kalkseifen im Darm die Resorption von Fetten verhindert und somit zu einer geringeren Absorption von Fett aus dem Darm führt (Jacobsen, R.; Lorenzen, J. K.; Toubro, S.; Krog-Mikkelsen, L; Astrup, A.; Intern J Obesity 29, S. 292 bis 301, 2005).Calcium is thought to prevent the absorption of fats through the formation of lime soaps in the intestines and thus to a lesser extent Absorption of fat from the gut (Jacobsen, R .; Lorenzen, JK; Toubro, S. Krog-Mikkelsen, L; Astrup, A .; Internal J Obesity 29, pp. 292 to 301, 2005).
Interessant ist es jedoch, dass in der Literatur darauf hingewiesen wird, dassIt is interesting, however, that it is pointed out in the literature that
Calcium immer auch mit Milchprodukten gemeinsam gegeben werden muss, wenn damit eine Gewichtsreduktion erzielt werden soll. Es gibt jedoch auch Arbeiten, die zeigen, dass eine Verwendung von Milchprodukten nicht unbedingt zum Erfolg führen muss (Günther, C. W. et al., Amer J Clin Nutr 81, S. 751 bis 756, 2005).Calcium must always be given together with dairy products if weight reduction is to be achieved. However, there are also studies showing that the use of dairy products does not necessarily lead to success (Günther, C.W. et al., Amer J Clin Nutr 81, pp. 751-756, 2005).
Die zuvor genannte Gewichtskontrolle durch Calcium wird auch im Gesamtbild des sogenannten Metabolischen Syndroms in medizinischen Kreisen diskutiert. Dabei spielt auch die Regulation des Blutdruckes eine Rolle. Es wur- de von verschiedenen Forschungsgruppen untersucht, ob die regelmäßigeThe aforementioned weight control by calcium is also discussed in the overall picture of the so-called metabolic syndrome in medical circles. The regulation of blood pressure also plays a role here. It was examined by various research groups whether the regular
Gabe von Calcium auch einen absenkenden Effekt auf einen erhöhten Blutdruck haben kann. Dazu gibt es verschiedene Untersuchungen ( D A McCar- ron M E Reusser, J Amer Coli Nutr, 18, 398S-405S (1999); R M Bosticck et al, Arch Fam Med, 9, 31-39 (2000); R Jorde K H Bonaa, Am J Clin Nutr 71, 1530-5 (2000); J J Mu et al. J Hum Hypertension 19, 479-483 (2005) ), die diese Wirkung von Calcium auf den Blutdruck bestätigt haben.Calcium may also have a lowering effect on increased blood pressure. There are several studies (DA McCarron ME Reusser, J Amer Coli Nutr, 18, 398S-405S (1999), RM Bosticck et al, Arch Fam Med, 9, 31-39 (2000), R Jorde KH Bonaa, J Clin Nutr 71, 1530-5 (2000); JJ Mu et al J Hum Hypertension 19, 479-483 (2005)), who have confirmed this effect of calcium on blood pressure.
Eine medizinisch ebenso interessante Anwendung von Calcium betrifft die Verhinderung der Auswirkungen des sogenannten Prämenstruellen Syndroms bei Frauen. Hier wird in der Literatur schon länger darauf verwiesen, dassA medically equally interesting application of calcium concerns the prevention of the effects of the so-called premenstrual syndrome in women. Here in the literature has long been pointed out that
Calcium eine lindernde Wirkung auf Depressionen, Angstzustände und Verstimmungen im Zusammenhang mit dem Prämenstruellen Syndrom bewirken kann ( S. Thys- Jacobs, J Amer Coli Nutr 19, 220-227(2000); E R Berto- ne Johnson et al. Arch Intern Med 11, 1246-52 (2005)) Aus den vorgenannten Gründen stellt die Versorgung des menschlichen Körpers mit Calcium ein gesundheitspolitisches Problem dar, für das zunehmend auch die Industrie Interesse zeigt. Hieran ist sowohl die pharmazeutische als auch die Lebensmittelindustrie interessiert.Calcium may have a palliative effect on depression, anxiety, and mood disorders associated with the premenstrual syndrome (S. Thys-Jacobs, J Amer Coli Nutr 19, 220-227 (2000); ER Bertone Johnson et al., Arch Intern Med , 1246-52 (2005)) For the reasons mentioned above, supplying the human body with calcium is a public health problem for which the industry is increasingly interested. This is of interest to both the pharmaceutical and food industries.
Aus dem Bereich der Lebensmittel gilt Milch als wichtigste Calciumquelle. Bedauerlicherweise hat der Verzehr von Milch in den letzten Jahren deutlich abgenommen, da zunehmend bei der Bevölkerung Mitteleuropas die so genannte Kuhmilchunverträglichkeit zugenommen hat. Im Prinzip kann statt Milch auch auf andere Milchprodukte zurückgegriffen werden, jedoch stehen die Konsumgewohnheiten der Verbraucher noch häufig entgegen. Deswegen wird Calcium in Lebensmittel zugesetzt, die dieses normalerweise nicht enthalten.In the food sector, milk is the most important source of calcium. Regrettably, the consumption of milk has declined significantly in recent years as so-called cow's milk intolerance has increasingly increased in the Central European population. In principle, other dairy products can be used instead of milk, but consumers' consumption habits are often still in conflict. Because of this, calcium is added to foods that do not normally contain it.
Auch die pharmazeutische Industrie versucht zunehmend mit Nahrungser- gänzungsmitteln hohe Mengen an Calcium herzustellen und anzubieten.The pharmaceutical industry is also increasingly trying to produce and supply high quantities of calcium with dietary supplements.
Für die meisten dieser Produkte werden jedoch Calciumsalze verwendet, die unlöslich sind, welche die biophysiologische Verfügbarkeit minimiert.For most of these products, however, calcium salts are used which are insoluble which minimizes biophysiological availability.
Aufgabe der Erfindung ist es daher, eine Calciumquelle für Produkte zu entwickeln, die Calcium in einer löslichen Form zur Verfügung zu stellen.The object of the invention is therefore to develop a source of calcium for products that provide calcium in a soluble form.
Zur Lösung der Aufgabe wird eine Calcium-Peptid-Komponente der eingangs genannten Art bereitgestellt, welche mindestens ein Calciumsalz, Casei- nophosphopeptide und Glycomakropeptid enthält.To achieve the object, a calcium-peptide component of the aforementioned type is provided, which contains at least one calcium salt, cagedophosphopeptides and glycomacropeptide.
Hierbei wird das Prinzip der Milch genutzt, nämlich die Bindung großerHere, the principle of milk is used, namely the binding of large
Menge des Calciums an Proteine. Von der Milch ist bekannt, dass das Calci- um gleichmäßig in der Flüssigkeit verteilt ist und nicht am Boden in Form ei- nes Bodensatzes abgelagert ist. Das Calcium in der Milch wird hauptsächlich an den so genannten Caseinen, einem Teil der Milchproteine gebunden. Bedauerlicherweise haben die Caseine den Nachteil, im Saueren auszufallen, sodass das gebundene Caseincalcium für saure Produkte ungeeignet ist.Amount of calcium in proteins. It is known from milk that the calcium is evenly distributed in the liquid and not at the bottom in the form of sediment is deposited. The calcium in the milk is mainly bound to the so-called caseins, a part of the milk proteins. Unfortunately, the caseins have the disadvantage of precipitating in the acid so that the bound casein calcium is unsuitable for acidic products.
Verschiede wissenschaftliche Forschungsgruppen haben sich in den letzten Jahren die Calciumbindung an das Casein näher untersucht und dabei das Prinzip der Calciumbindenden Peptide entdeckt. Dabei stellte sich heraus, dass bestimmte Abschnitte der Caseine Calcium besonders gut binden. Gleichzeitig verfugen diese Abschnitte über Proteingebundene Phosphatgruppen. Werden Caseine hydrolisiert, so entstehen u. a. Caseinophosphopep- tide, die Calcium besonders gut binden. Solche Caseinophosphopeptide werden heute kommerziell angeboten (z. B. CPP DMV). Durch die Verwendung von Caseinophosphopeptiden kann man heute weitgehend klare Calciumlö- sungen erzielen.Various scientific research groups have investigated calcium binding to casein in more detail over the last few years, discovering the principle of calcium-binding peptides. It turned out that certain sections of the caseins bind calcium particularly well. At the same time, these sections have protein-bound phosphate groups. Become hydrolyzed caseins, u arise. a. Caseinophosphopeptides, which bind calcium particularly well. Such caseinophosphopeptides are commercially available today (eg CPP DMV). Through the use of caseinophosphopeptides, it is now possible to achieve largely clear calcium solutions.
Bei der Herstellung von Käse wird durch die Wirkung des Labferments aus dem Casein das Glycomakropeptid freigesetzt. Dieses Glycomakropeptid befindet sich nach der Käseherstellung in der so genannten Molkenfraktion. Das Glycomakropeptid ist ein Fragment des κ-Caseins mit der Aminosäure-In the production of cheese, the action of the rennet casein releases the glycomacropeptide. This glycomacropeptide is located after cheese production in the so-called whey fraction. The glycomacropeptide is a fragment of κ-casein with the amino acid
Sequenz 106 bis 169. Glycomakropeptid enthält ebenfalls eine Phosphatgruppe, welche Calcium an sich binden kann.Sequence 106 to 169. Glycomacropeptide also contains a phosphate group which can bind calcium to itself.
Überraschenderweise hat sich nun herausgestellt, dass eine Mischung aus Ca- seinophosphopeptid und Glycomakropeptid wesentliche stabilere Calciumlö- sungen ergeben, die zudem physiologisch besser verwertbar sind.Surprisingly, it has now been found that a mixture of Ca-isophosphopeptide and Glycomakropeptid result in significantly more stable calcium solutions, which are also physiologically better usable.
Das Gewichtsverhältnis zwischen den Calciumsalzen, Caseinophosphopeptid und Glycomakropeptid beträgt vorzugsweise 1 - 5 : 0,5 - 2,5 : 1,5 - 7,5. Des Weiteren ist der Zusatz von Mineralstoffe und/oder Spurenelemente vorstellbar. Um Probleme der Ablagerung von Calcium in den Blutgefäßen zu vermeiden, kann der erfindungsgemäßen Calcium-Peptid-Komponente zusätzlich Magnesium zugegeben werden. Dabei können alle nach dem Le- bensmittelrecht erlaubten Magnesiumsalze zugesetzt werden. Als Tagesmenge wird eine Menge von maximal 250 mg Magnesium empfohlen.The weight ratio between the calcium salts, caseinophosphopeptide and glycomacropeptide is preferably 1 - 5: 0.5 - 2.5: 1.5 - 7.5. Furthermore, the addition of minerals and / or trace elements is conceivable. In order to avoid problems of deposition of calcium in the blood vessels, magnesium may additionally be added to the calcium-peptide component according to the invention. All magnesium salts permitted under the food law can be added. The daily amount recommended is a maximum of 250 mg of magnesium.
Vorzugsweise werden auch Vitamine zugesetzt; insbesondere Vitamin D, welches für die Resorption von Calcium im Dünndarm mitverantwortlich ist. Auch der Zusatz von löslichen Ballaststoffen, wie Oligofructose oder Galac- tooligosacchariden, und/oder Phytosterinen ist eine bevorzugte Ausführung der erfindungsgemäßen Komponente.Preferably, vitamins are also added; especially vitamin D, which is responsible for the absorption of calcium in the small intestine. The addition of soluble fiber, such as oligofructose or galactooligosaccharides, and / or phytosterols is a preferred embodiment of the component according to the invention.
Als Calciumsalze kommen alle lebensmittelrechtlich zugelassene Salze in Frage. Hier sind einige zu nennen: Calciumcarbonat, Calciumchlorid, Calci- umcitrate, Calciumgluconat, Calciumglycerophosphat, Calciumlactat, Calci- umorthophosphate, Calciumoxid und /oder Calciumhydroxid.Suitable calcium salts are all food-approved salts. Here are some to name: calcium carbonate, calcium chloride, calcium citrate, calcium gluconate, calcium glycerophosphate, calcium, calcium orthophosphate, calcium oxide and / or calcium hydroxide.
Des weiteren wurde festgestellt, dass die erfindungsgemäße Calcium-Peptid- Komponente in Tierversuchen eine Gewichtsreduzierungseigenschaft aufweist. Bei Ratten konnte beispielsweise eine geringere Gewichtszunahme und deutlich geringere Fettzunahme aufgezeichnet werden. Die gleiche Wirkung konnte ebenso bei Patienten nachgewiesen werden, die über Gewichtsprobleme klagten.Furthermore, it has been found that the calcium-peptide component according to the invention has a weight-reducing property in animal experiments. In rats, for example, a lower weight gain and significantly lower fat gain could be recorded. The same effect could also be demonstrated in patients complaining of weight problems.
Eine weitere Erfindung betrifft daher auch die Verwendung der erfindungsgemäßen Calcium-Peptid-Komponente als Arzneimittel, zur Herstellung eines Mittels zur Regulierung des Körpergewichts oder zur Verbesserung der Calciumresorption. Darüber hinaus betrifft die Erfindung die Verwendung der Calcium-Peptid- Komponente zur Herstellung eines Mittels zur Regulierung des Blutdruckes und zur Herstellung eines Mittels zur Linderung der Symptome des Prämenstruellen Syndroms.Another invention therefore also relates to the use of the calcium-peptide component according to the invention as a medicament, for the preparation of an agent for regulating body weight or for improving calcium absorption. Moreover, the invention relates to the use of the calcium-peptide component for the preparation of an agent for regulating blood pressure and for producing an agent for alleviating the symptoms of premenstrual syndrome.
Des weiteren betrifft die Erfindung auch die Verwendung der drei Hauptbestandteile Calciumsalze, Caseinophosphopeptide und Glycomakropeptide zur Herstellung von Präparaten zur Gewichtsreduzierung.Furthermore, the invention also relates to the use of the three main components calcium salts, caseinophosphopeptides and glycomacropeptides for the preparation of preparations for weight reduction.
Die erfindungsgemäße Calcium-Peptid-Komponente kann sowohl als Zusatzstoffe in Nahrungsmitteln, als Nahrungsergänzungsmittel oder als pharmazeutisches Präparat angeboten werden.The calcium-peptide component according to the invention can be offered both as additives in foods, as a dietary supplement or as a pharmaceutical preparation.
Die erfindungsgemäße Calcium-Peptid-Komponente ist vielseitig einsetzbar, insbesondere vorstellbar als Süßigkeit, Pulver, Tabletten, kompaktierte Formen, Riegel, Gelee oder Emulsionen.The calcium-peptide component according to the invention is versatile, in particular imaginable as candy, powder, tablets, compacted forms, bars, jellies or emulsions.
Typische Anwendungsbeispiele ist der Einsatz in Fruchtsäften, Quark- und Joghurt- Speisen, Molkendrinks, Desserts, Eiscreme, Calciumtabletten oder Früchteriegel.Typical application examples are the use in fruit juices, quark and yoghurt foods, whey drinks, desserts, ice cream, calcium tablets or fruit jars.
Die erfindungsgemäße Calcium-Peptid-Komponete kann wie folgt zusammengesetzt sein (als Beispiel wird die empfohlene Tagesdosis angegeben):The calcium-peptide component according to the invention can be composed as follows (the recommended daily dose is given as an example):
Bei einem weiteren Ausfuhrungsbeispiel handelt es sich um ein Komprimat hergestellt aus folgenden Rezepturkomponenten:In another exemplary embodiment, it is a compressed product made from the following formulation components:
Sorbit (72,75%)Sorbitol (72.75%)
Trennwachs (0,25%)Release wax (0.25%)
Magnesiumstearat (0,5%)Magnesium stearate (0.5%)
Trennwachs, flüssig (0,5%) tri-Calziumcitrat Tetrahydrat (10%) Glycomakropeptid (12%)Release wax, liquid (0.5%) tri-calcium citrate tetrahydrate (10%) glycomacropeptide (12%)
Caseinophosphopeptide (4%) Caseinophosphopeptides (4%)
Claims
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06754001A EP1903895A2 (en) | 2005-07-19 | 2006-05-31 | Calcium-peptide component |
| EA200800205A EA016259B1 (en) | 2005-07-19 | 2006-05-31 | Use of calcium-peptide component for weight reduction |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005033630A DE102005033630A1 (en) | 2005-07-19 | 2005-07-19 | Calcium-peptide component |
| DE102005033630.2 | 2005-07-19 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2007009529A2 true WO2007009529A2 (en) | 2007-01-25 |
| WO2007009529A3 WO2007009529A3 (en) | 2007-06-28 |
Family
ID=37575596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2006/005173 Ceased WO2007009529A2 (en) | 2005-07-19 | 2006-05-31 | Calcium-peptide component |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1903895A2 (en) |
| DE (1) | DE102005033630A1 (en) |
| EA (1) | EA016259B1 (en) |
| UA (1) | UA94716C2 (en) |
| WO (1) | WO2007009529A2 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008055801A3 (en) * | 2006-11-06 | 2008-12-04 | Humana Milchunion Eg | Antidiabetogenic calcium-peptide composition |
| WO2011137249A1 (en) * | 2010-04-28 | 2011-11-03 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
| US8492124B2 (en) | 2009-02-24 | 2013-07-23 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
| US9226933B2 (en) | 2004-07-22 | 2016-01-05 | Ritter Pharmaceuticals, Inc. | Methods and compositions for treating lactose intolerance |
| CN109805417A (en) * | 2019-03-01 | 2019-05-28 | 河南九九一生物科技有限公司 | A kind of health food that can increase bone density and its processing method |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007022694A1 (en) | 2007-05-11 | 2008-11-13 | Humana Milchunion Eg | Milk fat milk protein composition to improve calcium absorption |
| CN103445045A (en) * | 2012-05-30 | 2013-12-18 | 孔徐生 | Food composition having function of promoting calcium absorption and preparation method thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3373544B2 (en) * | 1991-12-05 | 2003-02-04 | 明治乳業株式会社 | Foods and drinks and pharmaceuticals with excellent calcium utilization that have the effect of alleviating dysmenorrhea |
| GB9927603D0 (en) * | 1999-11-22 | 2000-01-19 | Nestle Sa | Use of a milk protein hydrolysate in the treatment of diabetes |
| MXPA02010312A (en) * | 2000-04-18 | 2004-09-06 | Nestle Sa | Nutritional modules. |
| US6384087B1 (en) * | 2000-09-01 | 2002-05-07 | University Of Tennesseee Research Corporation, Inc. | Materials and methods for the treatment or prevention of obesity |
| GB0100273D0 (en) * | 2001-01-08 | 2001-02-14 | Nestle Sa | Nutritional composition for a bone condition |
| US20030165574A1 (en) * | 2002-03-01 | 2003-09-04 | Ward Loren Spencer | Compositions and methods for treatment of body weight conditions |
| JP2003048843A (en) * | 2002-07-17 | 2003-02-21 | Meiji Milk Prod Co Ltd | Functional food for prevention and / or treatment of dysmenorrhea |
-
2005
- 2005-07-19 DE DE102005033630A patent/DE102005033630A1/en not_active Withdrawn
-
2006
- 2006-05-31 UA UAA200801548A patent/UA94716C2/en unknown
- 2006-05-31 EA EA200800205A patent/EA016259B1/en not_active IP Right Cessation
- 2006-05-31 WO PCT/EP2006/005173 patent/WO2007009529A2/en not_active Ceased
- 2006-05-31 EP EP06754001A patent/EP1903895A2/en not_active Withdrawn
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9226933B2 (en) | 2004-07-22 | 2016-01-05 | Ritter Pharmaceuticals, Inc. | Methods and compositions for treating lactose intolerance |
| WO2008055801A3 (en) * | 2006-11-06 | 2008-12-04 | Humana Milchunion Eg | Antidiabetogenic calcium-peptide composition |
| EA016545B1 (en) * | 2006-11-06 | 2012-05-30 | Хумана Мильхунион Эг | Use of calcium-peptide composition for preventing and/or treating type ii diabetes |
| US8486668B2 (en) | 2009-02-24 | 2013-07-16 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
| US8492124B2 (en) | 2009-02-24 | 2013-07-23 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
| US8785160B2 (en) | 2009-02-24 | 2014-07-22 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
| US9579340B2 (en) | 2009-02-24 | 2017-02-28 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
| US9592248B2 (en) | 2009-02-24 | 2017-03-14 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
| US9775860B2 (en) | 2009-02-24 | 2017-10-03 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
| US9808481B2 (en) | 2009-02-24 | 2017-11-07 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
| WO2011137249A1 (en) * | 2010-04-28 | 2011-11-03 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
| CN109805417A (en) * | 2019-03-01 | 2019-05-28 | 河南九九一生物科技有限公司 | A kind of health food that can increase bone density and its processing method |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007009529A3 (en) | 2007-06-28 |
| UA94716C2 (en) | 2011-06-10 |
| EA200800205A1 (en) | 2008-08-29 |
| EP1903895A2 (en) | 2008-04-02 |
| DE102005033630A1 (en) | 2007-01-25 |
| EA016259B1 (en) | 2012-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60310934T2 (en) | COMPOSITION REQUIRING SATURATION FEELING | |
| DE69233250T2 (en) | COMBINATIONS OF CALCIUM AND VITAMIN D | |
| DE60126104T2 (en) | NUTRITIONAL COMPOSITION AND METHOD FOR IMPROVING THE DISPOSAL OF PROTEINS | |
| JP5775657B2 (en) | Anti-fatigue agent containing amino acid composition | |
| EP2114174B1 (en) | Use of guanidinoacetic acid (salts) combined with betaine and/or choline for producing a health-promoting agent | |
| EP2680713B1 (en) | Composition for nutrition purposes | |
| CN111616232A (en) | Children milk powder for promoting bone growth and preparation method thereof | |
| AU2002221860A1 (en) | Nutritional composition for an immune condition | |
| JP2001158736A (en) | Agent for preventing and improving osteoarthropathy | |
| WO2002039834A1 (en) | Nutritional composition for an immune condition | |
| DE60315842T2 (en) | USE OF HESPERIDINE OR ITS DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR STIMULATING BONE FORMATION | |
| WO2008138821A1 (en) | Milk fat-milk protein composition (preferably esterified with palmitic acid) for improving calcium absorption | |
| DE69922409T2 (en) | Use of natural antisecretory proteins | |
| EP1903895A2 (en) | Calcium-peptide component | |
| WO2010061877A1 (en) | Mineral absorption improver, and method for improving absorption of minerals | |
| DE20300380U1 (en) | Low-fat ice-cream useful for promoting health and enhancing performance includes isoflavone-containing soya protein and animal protein | |
| WO2005097146A2 (en) | Dairy components effective for fat loss | |
| AT10252U1 (en) | PROTEIN PREPARATION | |
| CN102596212A (en) | Use of extracts from salonum glaucophyllum for treating bone metabolism disorders and kidney disorders | |
| EP1862197A2 (en) | Use of a protein concentrate | |
| EP2089046A2 (en) | Antidiabetogenic calcium-peptide composition | |
| JP3248170B2 (en) | Food containing chondroitin sulfate protein complex | |
| DE102004005338A1 (en) | Calcium-fortified foods | |
| JPH1146720A (en) | Nutritive composition for promoting absorption of calcium | |
| DE2054769A1 (en) | Diet pasta |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WWE | Wipo information: entry into national phase |
Ref document number: 2006754001 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 200800205 Country of ref document: EA |
|
| WWP | Wipo information: published in national office |
Ref document number: 2006754001 Country of ref document: EP |